Boston Scientific (NYSE: BSX) reported Q2 EPS of $0.44, $0.02 better than the analyst estimate of $0.42. Revenue for the quarter came in at $3.24 billion versus the consensus estimate of $3.21 billion.

GUIDANCE:

Boston Scientific sees FY2022 EPS of $1.74-$1.77, versus the consensus of $1.76.

For earnings history and earnings-related data on Boston Scientific (BSX) click here.